Keith McCullagh is an experienced pharmaceutical research & development executive and bioscience entrepreneur. He was a co-founder of Metrion and previously chairman of Xention, Ario Pharma, Affitech, Pharmacy 2U and Clavis Pharma and Chief Executive of Santaris Pharma, an RNA medicines company sold to Roche in 2014.

From 1986 to 1998, Keith was Chief Executive of British Biotech, now Vernalis (a subsidiary or Hitgen), a company he founded and built into one of Europe’s first public biopharmaceutical businesses. Prior to British Biotech, he was UK Research Director for GD Searle & Co, Inc., now part of Pfizer.

He holds a degree in Veterinary Medicine from the University of Bristol and a PhD in Pathology from the University of Cambridge.